Analysts Offer Predictions for AVIR Q1 Earnings

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) – Stock analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Atea Pharmaceuticals in a research report issued on Friday, March 7th. William Blair analyst A. Hsieh forecasts that the company will post earnings of ($0.40) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Atea Pharmaceuticals’ current full-year earnings is ($2.01) per share. William Blair also issued estimates for Atea Pharmaceuticals’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.59) EPS and FY2027 earnings at ($1.60) EPS.

Atea Pharmaceuticals Stock Performance

Atea Pharmaceuticals stock opened at $2.92 on Monday. The stock has a market capitalization of $246.63 million, a P/E ratio of -1.41 and a beta of 0.18. The company’s fifty day moving average price is $3.15 and its 200 day moving average price is $3.33. Atea Pharmaceuticals has a 1 year low of $2.75 and a 1 year high of $4.18.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05).

Institutional Trading of Atea Pharmaceuticals

Several institutional investors have recently modified their holdings of AVIR. Intech Investment Management LLC purchased a new position in Atea Pharmaceuticals in the 3rd quarter valued at about $36,000. Dynamic Technology Lab Private Ltd purchased a new stake in Atea Pharmaceuticals during the 3rd quarter worth approximately $37,000. Graham Capital Management L.P. acquired a new position in shares of Atea Pharmaceuticals during the fourth quarter valued at approximately $42,000. Millennium Management LLC purchased a new position in shares of Atea Pharmaceuticals in the fourth quarter valued at approximately $75,000. Finally, Zacks Investment Management purchased a new position in shares of Atea Pharmaceuticals in the third quarter valued at approximately $80,000. Institutional investors and hedge funds own 86.67% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.